|
|
Home >> Our Advantage > Alliances
|
|
|
|
 |
 |
|
Panacea Biotec enjoys a rich tradition of collaborations and joint ventures with various industry players and business relationships with national & international research institutes, academic universities and commercial corporations for the purpose of securing in-licensing, out sourcing and other business opportunities and to develop strong product portfolio. |
| |
| Nederlands Vaccine Institute (NVI), Netherlands. |
The Company has entered into an agreement with NVI for manufacturing and marketing of Inactivated Polio Vaccine in global markets except Netherlands, Denmark, Norway and Finland. |
| |
| National Research Development Corporation (NRDC), India. |
The Company has an in-licensing arrangement with NRDC for manufacturing the Foot and Mouth Disease (FMD) vaccine developed by Indian Veterinary Research Institute (IVRI). |
| |
| PT Bio Farma, Indonesia. |
The Company has entered into an agreement with PT. Bio Farma, Indonesia to manufacture & market the Measles Vaccine and plans to supply the vaccine to UNICEF, PAHO and CIS, African, LATAM and Asian Countries in furtherance to Global Measles Reduction Strategy of WHO and UNICEF. |
|
| |
| Chiron Panacea Vaccines Pvt. Ltd. (“Chiron Panacea”) |
Chiron Panacea is a joint venture company incorporated in fiscal 2005 in India with Chiron Corporation, U.K. (now Novartis Vaccines), world’s 5th largest Vaccine group, for marketing of combination and other vaccines in India. The Company has invested Rs.22.9 million in Chiron Panacea for a 50.0% equity stake. |
| |
| National Institute of Health, USA. |
The Company has an in-licensing arrangement with National Institute of Health, USA, for use of a peptide based product for generation of hair follicles and hair growth. Pre-clinical toxicology studies will be shortly initiated. |
| |
| National Institute of Immunology, India. |
The Company has an exclusive ten-year license agreement with National Institute of Immunology, India for in-licensing of technology and processes for production of tissue culture derived formalin inactivated, Japanese encephalitis vaccine. The technology transfer and training of scientists has been completed and scale-up production for clinical trial purposes and optimization of various analytical and biological test methods, is under progress. |
| |
| Cambridge Biostability Ltd., U.K. |
The Company has an existing collaboration with Cambridge Biostability Ltd. (CBL), a U.K. based Company for developing thermostable vaccines applying CBL’s patented ‘Stable Liquid Technology’ over the Company’s existing range of vaccines. During the year under review, the Company entered into a joint venture and made investment of Rs.168.07 Million (£1.94 Million) for acquiring 10% of the share capital in CBL. CBL was formed in 1998 in England & Wales and has a R&D facility in Cambridge, which is developing its technology for applications in developing countries, Biodefence and multivalent vaccines for sale in developed countries. |
| |
| Biotech Consortium India Ltd. |
The Company has a ten-year in-licensing arrangement with Biotech Consortium India Ltd. for the development, manufacture and marketing of anthrax vaccine developed by Jawahar Lal Nehru University, India. Phase I/IIa of human trials have been successfully completed and the Phase-IIb clinical trials are to begin shortly, subsequent to which the company plan to supply the anthrax vaccine to the U.S. government. For this purpose, the Company plans to initiate discussion with a U.S. based vaccine company for collaboration. |
| |
|
